The scheduled NCLT hearing for India Glycols Ltd's Scheme of Arrangement, initially slated for May 21, 2026, has been postponed. A new hearing date is yet to be announced.

India Glycols Ltd has initiated mediation to challenge a ₹79.8 crore insurance claim rejection, stemming from damage to plant machinery at their Kashipur facility in 2020. The dispute is with New India Assurance over the insurance claim.

India Glycols reported a 28.6% increase in Q4 net profit for FY26, despite a 11.4% drop in revenue. The company's operating margins reached multi-quarter highs, yet the stock price fell by 5.2%, possibly due to investor concerns about the declining revenue.

India Glycol's share price declined approximately 5% due to the company reporting weak Q4 earnings, potentially indicating challenges in their recent performance.

India Glycols reports a significant 57% year-over-year (YoY) increase in Q4 EBITDA, reaching ₹2.33 billion, up from ₹1.48 billion. The company's margins also improved substantially, rising to 9.9% compared to 6.8% in the same period last year, marking a notable 3.1 percentage point expansion.

India Glycols' fourth-quarter profits rose by 36%, and EBITDA increased by 14%. This strong performance suggests a robust growth trajectory for the company.

India Glycols Ltd will release its audited financial results at a board meeting on May 14, 2026. Trading of the company's shares has been suspended from April 1 to May 16 in accordance with their policy.

India Glycols Ltd's valuation has moved from 'attractive' to 'fair', as of April 2026, indicating solid historical earnings yet intensifying competition within the commodity chemicals industry.